🇺🇸 Regeneron Pharmaceuticals, Inc.
Forum topic · REGN · Company page: financials, ownership and filings
Join the discussion on Regeneron Pharmaceuticals, Inc.
Loading…
Insider trading in October 2026
Directors and officers of Regeneron Pharmaceuticals, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 4 insiders sold shares worth about $6,236,446 in 30 trades.
Awards, option exercises and shares withheld for tax are not counted.
Mutual funds: 900 funds hold $26.7 billion
900 mutual funds in 3 countries hold shares of Regeneron Pharmaceuticals, Inc. worth $26.7 billion, about 38.1% of the company (funds' newest reports, up to 31 October 2026).
Since their previous reports 411 funds added shares and 414 sold; on balance they sold $767 million. Share splits are not counted as trading.
Results announced on 30 October 2026
Regeneron Pharmaceuticals, Inc. announced results on 30 October 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $5.1 billion (up 36% from a year earlier) and net income of $1.9 billion (up 33% from a year earlier).
Results announced on 6 October 2026
Regeneron Pharmaceuticals, Inc. announced results on 6 October 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $5.1 billion (up 36% from a year earlier) and net income of $1.9 billion (up 33% from a year earlier).
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.